|Bid||44.46 x 1100|
|Ask||45.26 x 800|
|Day's Range||44.55 - 46.49|
|52 Week Range||30.87 - 49.55|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.00|
An IPO that happened on Thursday, a filing for another one, and more than $600 million in funding tops the Bay Area's venture news heading into the holiday weekend.
All six have doubled in value — or more — since their Wall Street debuts and they are either headquartered in the Bay Area or backed by investors from the region.
A South San Francisco biotech's offering soared on Thursday, but a San Mateo ruggedized smartphone maker's priced well below its targets. Here's more on that and other Bay Area founder and funder news at the end of the week.
SUNNYVALE, Calif., May 08, 2019 -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial.
Beyond Meat’s reliance on co-manufactures and related disputes with former manufacturing partners point to a potential risk for a company that just had the best first-day IPO of the year.
The measure of the health of the venture and startup world has dropped for two straight quarters now, down from 17-year highs by about 15 percent.
Silk Road Medical, Inc. (SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV. Silk Road Medical’s management is scheduled to present on Wednesday, May 15 at 11:20 a.m. Pacific Time. Silk Road Medical, Inc. is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact.
The company joins joins what could be a busy month for Bay Area IPOs in May, which is expected to include Uber's massive offering, Slack's direct listing and the market debut of South San Francisco biotech Cortexyme.
Silk Road Medical, Inc. (SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2019 after market close on Wednesday, May 8, 2019. Investors interested in listening to the conference call may do so by dialing (844) 883-3861 for domestic callers or (574) 990-9820 for international callers, using conference ID: 5758256. Silk Road Medical, Inc. is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact.
Silk Road Medical, Inc. (SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the closing of its initial public offering of 6,000,000 shares of common stock, and the exercise in full of the underwriters’ option to purchase 900,000 additional shares of common stock from the selling stockholders, at a public offering price of $20 per share. The gross proceeds from the offering were approximately $120 million, before deducting underwriting discounts and commissions and estimated offering expenses. Silk Road Medical did not receive any proceeds from the sale of the shares of common stock by the selling stockholders. J.P. Morgan Securities LLC and BofA Merrill Lynch acted as joint book-running managers for the offering.
Another unicorn is lining up an IPO for later this year and 10 Bay Area companies raised about $175 million in funding at week's end. Here are the details.
Shares of the Silk Road Medical IPO jumped 80.9% on the first day of trading, with an initial public offering that drew heavy interest from investors for the medical device company.
Shares of Silk Road Medical Inc. soared in their public debut Thursday, enough to pace all gainers on the major U.S. exchanges. The first trade was at $33.15, or 66% above the $20 initial public offering price, at 11:36 a.m. Eastern. Since then, the stock has traded in a range of $32.73 to $37.30, and was recently 85% above its IPO price at $36.96. The medical device company sold 6 million shares in the IPO to raise $120 million, and could raise up to $138 million if the underwriters exercise all the options granted to buy additional shares. At the IPO price, the company was valued at $604.2 million. The IPO priced at the top of the expected range of $19 to $20, up from original expectations of $15 to $17, when the company said it has expected to offer 4.7 million shares for sale. The company went public at a time that the Renaissance IPO ETF has run up 32% year to date, while the S&P 500 has gained 15%.
Silk Road Medical Inc will hit the Nasdaq under ticker SILK on Thursday. Here’s what you should know before making a bid. The Offering Silk Road said it would issue nearly 4.7 million shares between $15 ...
Silk Road Medical, Inc. (SILK) (“Silk Road Medical”) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $20.00 per share. All of the shares of common stock are being offered by Silk Road Medical. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
The Silk Road Medical IPO priced at 20 a share, at the high end of its expected range, after one IPO research firm gave the offering its highest rating.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Ruhnn Holding Ltd (RUHN) will issue 10 million shares between $11.50 ...